PCM
ALXN

Peregrine Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Peregrine Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-153,810
Closed -$13.8M – 325
2020
Q1 		$13.8M Buy
153,810
+1,196
+0.8% +$117K 0.5% 77
2019
Q4 		$16.5M Buy
152,614
+587
+0.4% +$62.8K 0.42% 109
2019
Q3 		$14.9M Sell
152,027
-13,859
-8% -$1.56M 0.41% 112
2019
Q2 		$21.7M Hold
165,886
– – 0.54% 65
2019
Q1 		$22.4M Buy
165,886
+1,963
+1% +$244K 0.56% 54
2018
Q4 		$16M Buy
163,923
+14,315
+10% +$1.69M 0.45% 88
2018
Q3 		$20.8M Hold
149,608
– – 0.49% 83
2018
Q2 		$18.6M Buy
149,608
+457
+0.3% +$53.4K 0.46% 89
2018
Q1 		$16.6M Buy
149,151
+22,831
+18% +$2.73M 0.41% 102
2017
Q4 		$15.1M Buy
126,320
+28,900
+30% +$3.52M 0.36% 115
2017
Q3 		$13.7M Hold
97,420
– – 0.33% 124
2017
Q2 		$11.9M Buy
97,420
+19,427
+25% +$2.26M 0.3% 141
2017
Q1 		$9.41M Sell
77,993
-38,854
-33% -$5.01M 0.24% 179
2016
Q4 		$14.3M Hold
116,847
– – 0.37% 108
2016
Q3 		$14.3M Buy
+116,847
New +$15M 0.37% 110

Other funds holding ALXN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Peregrine Capital Management's ALXN Position: Q2 2020 in Review

Peregrine Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 153,810 shares — an estimated $13.8M sold.

Peregrine Capital Management first reported a position in ALXN in Q3 2016 and held it in 15 quarters. The position peaked at $22.4M in Q1 2019. 706 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Peregrine Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Peregrine Capital Management sold 153,810 Alexion Pharmaceuticals shares in Q2 2020, an estimated $13.8M.
  • Peregrine Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 15 quarters.
  • Peregrine Capital Management's Alexion Pharmaceuticals position peaked at $22.4M in Q1 2019.
  • 706 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Peregrine Capital Management's 13F filing for Q2 2020, filed 30 Jul 2020.